Targeting CHFR through PARP-inhibition: A novel strategy to overcome taxane resistance in adenocarcinomas of the lung

Targeted Therapeutics Research Award
LUNGevity Foundation/Uniting Against Lung Cancer Research Grant
Johan C. Brandes, MD, PhD
Emory University
Atlanta
GA

The PARP protein is a protein that protects cancer cells from being killed by chemotherapy. Dr. Brandes is determining how drugs that stop the PARP protein can be used for targeted therapy of non-small cell lung cancer.